NCT04892017View on ClinicalTrials.gov

A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Interventions
DRUG

Inlexisertib

Oral Tablet Formulation

DRUG

Trametinib

Oral Tablet Formulation

DRUG

Binimetinib

Oral Tablet Formulation

DRUG

Sotorasib

Oral Tablet Formulation

Trial Locations (10)

10016

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York

19104

Hospital of the University of Pennsylvania, Philadelphia

53792

University of Wisconsin Clinical Science Center, Madison

63108

Washington University Siteman Cancer Center, St Louis

77030

The University of Texas MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

78758

NEXT Oncology, Austin

97239

Oregon Health and Science University, Portland

02114

Massachusetts General Hospital, Boston

08901

Rutgers Cancer Institute, New Brunswick

Sponsors
All Listed Sponsors
lead

Deciphera Pharmaceuticals, LLC

INDUSTRY